Logo

Affibody and NCI to Develop Molecular In Vivo Imaging Agents

Nov 08, 2005

NEW YORK, Nov. 8 (GenomeWeb News) - Affibody and the National Cancer Institute plan to co-develop conjugates with Affibody molecules to be used for in vivo imaging, the Swedish company said today.

 

The agreement combines Affibody's internally developed technology with the US National Institute of Health's conjugation systems.

 

Affibody will develop engineered Affibody molecules specific for HER2, a receptor protein sometimes over-expressed in breast and ovarian cancers. NCI will conjugate the engineered molecules with detection molecules for evaluation.

 

Additional details were not disclosed.

Breaking News
The Scan

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.

SpliceVault Portal Provides Look at RNA Splicing Changes Linked to Genetic Variants

The portal, described in Nature Genetics, houses variant-related messenger RNA splicing insights drawn from RNA sequencing data in nearly 335,700 samples — a set known as the 300K-RNA resource.

Automated Sequencing Pipeline Appears to Allow Rapid SARS-CoV-2 Lineage Detection in Nevada Study

Researchers in the Journal of Molecular Diagnostics describe and assess a Clear Labs Dx automated workflow, sequencing, and bioinformatic analysis method for quickly identifying SARS-CoV-2 lineages.

UK Team Presents Genetic, Epigenetic Sequencing Method

Using enzymatic DNA preparation steps, researchers in Nature Biotechnology develop a strategy for sequencing DNA, along with 5-methylcytosine and 5-hydroxymethylcytosine, on existing sequencers.